Cell-free DNA as a prognostic marker in stage I non-small-cell lung cancer patients undergoing stereotactic body radiotherapy

Biomarkers

Volumn 20, Issue 6-7, 2015, Pages 422-428

  Bortolin, Maria Teresa ^a   Tedeschi, Rosamaria ^a   Bidoli, Ettore ^a   Furlan, Carlo ^a   Basaglia, Giancarlo ^a   Minatel, Emilio ^a   Gobitti, Carlo ^a   Franchin, Giovanni ^a   Trovò, Marco ^a   De Paoli, Paolo ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Biomarker; cell free DNA; early stage; lung cancer; stereotactic body radiotherapy

Indexed keywords

CELL FREE DNA; DNA; FLUORODEOXYGLUCOSE F 18; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; TUMOR MARKER;

AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CELL FREE SYSTEM; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MALE; NON SMALL CELL LUNG CANCER; POSITRON EMISSION TOMOGRAPHY; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SMOKING HABIT; STEREOTACTIC BODY RADIATION THERAPY; TUMOR GROWTH; TUMOR RECURRENCE; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; LUNG NEOPLASMS; PROCEDURES; PROGNOSIS; RADIOSURGERY; SURVIVAL ANALYSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; DNA, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PROGNOSIS; RADIOSURGERY; SURVIVAL ANALYSIS;

EID: 84948720217     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2015.1094139     Document Type: Article

References (40)

1. Baumann P, Nyman J, Hoyer M, et al. (2009). Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 27: 3290-6
2. Beau-Faller M, Gaub MP, Schneider A, et al. (2003). Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer patients. Int J Cancer 105: 361-70
3. Boyd JA, Hubbs JL, Kim DW, et al. (2010). Timing of local and distant failure in resected lung cancer: implications for reported rates of local failure. J Thorac Oncol 5: 211-14
4. Brock J, Ashley S, Bedford J, et al. (2008). Review of hypofractionated small volume radiotherapy for early-stage non-small cell lung cancer. Clin Oncol (R Coll Radiol) 20: 666-76
5. Catarino R, Coelho A, Araújo A, et al. (2012). Circulating DNA: diagnostic tool and predictive marker for overall survival of NSCLC patients. PLoS One 7: e38559
6. Chansky K, Sculier JP, Crowley JJ, et al. (2009). International Staging Committee and Participating Institutions. The International Association for The Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 4: 792-801
7. Cheng C, Omura-Minamisawa M, Kang Y, et al. (2009). Quantification of circulating cell-free DNA in The plasma of cancer patients during radiation therapy. Cancer Sci 100: 303-9
8. DeLong ER, DeLong DM, Clarke-Pearson DL. (1988). Comparing The areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44: 837-45
9. Devonshire AS, Whale AS, Gutteridge A, et al. (2014). Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. Anal Bioanal Chem 406: 6499-512
10. Elshimali YI, Khaddour H, Sarkissyan M, et al. (2013). The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci 14: 18925-58
11. Esposito A, Bardelli A, Criscitiello C, et al. (2014). Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities. Cancer Treat Rev 40: 648-55
12. Ferlay J, Shin HR, Bray F, et al. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-917
13. Fournié GJ, Courtin JP, Laval F, et al. (1995). Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumours. Cancer Lett 91: 221-7
14. Gautschi O, Bigosch C, Huegli B, et al. (2004). Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol 22: 4157-64
15. Gormally E, Caboux E, Vineis P, Hainaut P. (2007). Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res 635: 105-17
16. Guckenberger M, Allgäuer M, Appold S, et al. (2013). Safety and efficacy of stereotactic body radiotherapy for stage 1 non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis. J Thorac Oncol 8: 1050-8
17. Hidetaka U, Fumihiro T. (2014). Recurrence after surgery in patients with NSCLC. Transl Lung Cancer Res 3: 242-9
18. Howington JA, Blum MG, Chang AC, et al. (2013). Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143: e278S-313S
19. Kumar S, Guleria R, Mohan A, et al. (2011). Efficacy of plasma TGF-β1 level in predicting therapeutic efficacy and prognosis in patients with advanced non-small cell lung cancer. Cancer Invest 29: 202-7
20. Martini N, Bains MS, Burt ME, et al. (1995). Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 109: 120-9
21. Paci M, Maramotti S, Bellesia E, et al. (2009). Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. Lung Cancer 64: 92-7
22. Palmer JD, Zaorsky NG, Witek M, Lu B. (2014). Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer. J Thorac Dis 6: 387-98
23. Pathak AK, Bhutani M, Kumar S, et al. (2006). Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chem 52: 1833-42
24. Ricardi U, Filippi AR, Guarneri A, et al. (2010). Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial. Lung Cancer 68: 72-7
25. Ricardi U, Frezza G, Filippi AR, et al. (2014). Stereotactic ablative radiotherapy for stage I histologically proven non-small cell lung cancer: an Italian multicenter observational study. Lung Cancer 84: 248-53
26. Sandhu AP, Lau SK, Rahn D, et al. (2014). Stereotactic body radiation therapy in octogenarians with stage I lung cancer. Clin Lung Cancer 15: 131-5
27. Senthi S, Lagerwaard FJ, Haasbeek CJ, et al. (2012). Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol 13: 802-9
28. Sirera R, Bremnes RM, Cabrera A, et al. (2011). Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer. J Thorac Oncol 6: 286-90
29. Socinski MA, Morris DE, Masters GA. (2003). American College of Chest Physicians. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 123: 226S-43S
30. Sozzi G, Conte D, Leon M, et al. (2003). Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 21: 3902-8
31. Sozzi G, Conte D, Mariani L, et al. (2001). Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res 61: 4675-8
32. Sozzi G, Roz L, Conte D, et al. (2009). Plasma DNA quantification in lung cancer computed tomography screening: five-year results of a prospective study. Am J Respir Crit Care Med 179: 69-74
33. Suresh KP, Chandrashekara S. (2012). Sample size estimation and power analysis for clinical research studies. J Hum Reprod Sci 5: 7-13
34. Tantraworasin A, Saeteng S, Lertprasertsuke N, et al. (2013). Completely resected n0 non-small cell lung cancer: prognostic factors affecting long-term survival. ISRN Surg 175304
35. Timmerman R, Paulus R, Galvin J, et al. (2010). Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303: 1070-6
36. Trakul N, Chang CN, Harris J, et al. (2012). Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors. Int J Radiat Oncol Biol Phys 84: 231-7
37. van der Drift MA, Hol BE, Klaassen CH, et al. (2010). Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer. Lung Cancer 68: 283-7
38. Wang S, Han X, Hu X, et al. (2014). Clinical significance of pretreatment plasma biomarkers in advanced non-small cell lung cancer patients. Clin Chim Acta 430: 63-70
39. Yoon KA, Park S, Lee SH, et al. (2009). Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls. J Mol Diagn 11: 182-5
40. Zhang R, Shao F, Wu X, Ying K. (2010). Value of quantitative analysis of circulating cell free DNA as a screening tool for lung cancer: a meta-analysis. Lung Cancer 69: 225-31